Skip to main content

Dr. Reddy's Laboratories Ltd

corporate_fare Company Profile

Dr. Reddy's Laboratories Ltd

RDY·NYSE·Life Sciences·CIK 0001135951

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Dr. Reddy's Laboratories Ltd (NYSE:RDY) is a publicly traded company in the Life Sciences sector. Wiseek monitors RDY SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Dr. Reddy's Acquires Key Hormone Replacement Therapy Brands in India for $32.15M
  • Dr. Reddy's Global Head of IPDO Resigns, Effective May 2026
  • Dr. Reddy's Reports Q3 FY26 Profitability Decline and USFDA Denosumab Biosimilar CRL
  • Dr. Reddy's Q3 Profitability Declines 14% Amid Biosimilar Setbacks and Lower Lenalidomide Sales
  • Dr. Reddy's Reports Significant Q3 Profit Decline Amidst Revenue Growth and Ongoing Legal/Regulatory Scrutiny

Financial Snapshot

Fiscal year ended March 31, 2026
Revenue
$3.58B
Net Income
$452M
Diluted EPS
$0.55
Op. Cash Flow
$607M
Free Cash Flow
$358M
Gross Profit
$1.89B
Operating Income
$539M
Cash & Equivalents
$164M
Total Debt
$194M
Debt / Equity
0.05×
Net Margin
12.6%
Shares Outstanding
832M sh
Source: 20-F · filed 2026-05-29 · accession 0001575872-26-000381

Insider Transactions

RDY files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$11.85 +0.08% today
52-week range · as of 2026-07-22 $11.54 – $15.67
Market cap
$9.91B
Volume
4.1M (1.3× avg)
3-mo avg 3.1M
Live data · 2026-07-29 11:20 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed RDY - Filings & News (Page 2)

RDY
Feb 18, 2026, 11:03 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.35
Real-time Price: $11.85 info
Change: -$2.50 (-17%) info
Market Cap: $9.907B info
RDY
Feb 10, 2026, 7:54 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.08
Real-time Price: $11.85 info
Change: -$2.23 (-16%) info
Market Cap: $9.907B info
RDY
Jan 21, 2026, 12:57 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $13.31
Real-time Price: $11.85 info
Change: -$1.46 (-11%) info
Market Cap: $9.907B info
RDY
Jan 21, 2026, 12:28 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $13.33
Real-time Price: $11.85 info
Change: -$1.48 (-11%) info
Market Cap: $9.907B info
RDY
Jan 21, 2026, 11:22 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $13.26
Real-time Price: $11.85 info
Change: -$1.41 (-11%) info
Market Cap: $9.907B info
RDY
Jan 15, 2026, 6:09 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $13.30
Real-time Price: $11.85 info
Change: -$1.45 (-11%) info
Market Cap: $9.907B info
RDY
Jan 12, 2026, 6:08 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $13.40
Real-time Price: $11.85 info
Change: -$1.55 (-12%) info
Market Cap: $9.907B info